Immune-Targeting Drug Combo Shows Promise for Non-Small Cell Lung Cancer Patients, Say Moffitt Cancer Center Researchers (Moffitt Cancer Center)

Lung cancer is the most common cause of cancer-related death in the United States resulting in more than 158,000 deaths each year. With a five-year survival rate at only 18 percent, the development of new and improved treatment options is needed. Moffitt Cancer Center researchers are leading the way in the creation of novel therapies. Most recently, Moffitt, in conjunction with partner institutions, initiated a multicenter phase 1b clinical trial to determine the safety and efficacy of a new dru...
Source: National Comprehensive Cancer Network - Category: Cancer & Oncology Source Type: news